We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Read MoreHide Full Article
Key Takeaways
IART trades well below industry, sector and S&P 500 forward earnings multiples.
IART's margin gains and cost savings are supporting earnings as sales growth remains modest.
IART faces elevated leverage, refinancing costs and unresolved FDA remediation risks.
Integra LifeSciences Holdings Corp. (IART - Free Report) trades at a steep valuation discount, while recent margin gains and better operating execution offer support for the earnings outlook. The gap versus industry and market benchmarks gives value investors a reason to look closer.
The trade-off is that revenue growth remains modest, leverage is elevated and regulatory remediation is unfinished. That combination makes execution more important than the headline multiple alone.
IART’s Valuation Offers a Clear Discount
IART trades at 6.96X forward 12-month earnings, compared with 26.19X for its Zacks sub-industry, 21.43X for the broader Zacks Medical sector and 20.50X for the S&P 500. The discount is substantial across each benchmark.
Image Source: Zacks Investment Research
The stock also sits below its five-year median forward multiple of 11.00X. That suggests investors are still assigning a sizable discount for company-specific uncertainty despite the recent improvement in operating performance.
Integra’s Earnings Outlook Shows Measured Growth
The Zacks Consensus Estimate calls for 2026 revenues of $1.68 billion and earnings of $2.46 per share. For 2027, the consensus estimate stands at $1.74 billion in revenues and $2.56 per share in earnings.
Image Source: Zacks Investment Research
Projected earnings growth for the current fiscal year is 10.3%, while projected sales growth is 2.6%. The gap implies that margin delivery and cost execution will carry more weight than top-line expansion in supporting the earnings case.
IART’s Operating Improvements Strengthen the Case
Second-quarter 2026 adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by 16.7%. Adjusted EBITDA increased 10.1% to $78.4 million, while the adjusted EBITDA margin expanded 160 basis points to 18.7%.
Manufacturing efficiencies, lower remediation spending and margin-improvement initiatives supported the quarter. Integra also expects $25-$30 million of savings in 2026, with another $10-$15 million of annualized savings in 2027.
Competition remains relevant as supply reliability improves. Medtronic plc (MDT - Free Report) offers a broad neurosurgery portfolio spanning cranial repair, shunts, powered surgical equipment and navigation, while Stryker Corporation (SYK - Free Report) markets neurosurgical technologies including ultrasonic aspirators, high-speed drills and navigation systems. That breadth reinforces the importance of consistent execution for Integra.
Integra’s Debt and FDA Risks Argue for Patience
Net debt stood at $1.60 billion at the end of the second quarter, while total leverage was 4.1X, above management’s 2.5X-3.5X target range. Interest expense rose to $23.0 million from $21.0 million a year earlier, and management expects higher interest expense in the second half as it evaluates refinancing options.
Regulatory risk remains another constraint. The December 2024 FDA warning letter is unresolved, and related Class III premarket approvals cannot be cleared until relevant violations are corrected. Braintree is producing SurgiMend, but its premarket approval still requires a successful pre-approval inspection.
IART’s Value Score Stands Out Amid Mixed Signals
The valuation case is clear, but the operating and balance-sheet risks keep the setup from becoming a simple low-multiple story. Earnings improvement and cost savings help, while modest sales growth, refinancing costs and FDA remediation limit visibility.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B supports the discount argument, but the Growth Score of C, VGM Score of C and Momentum Score of D are less supportive. Because the Style Scores are designed to complement the Zacks Rank, the current mix favors a measured view rather than treating valuation alone as an unequivocal buy signal.
View the Zacks #1 Rank List
Image: Bigstock
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Key Takeaways
Integra LifeSciences Holdings Corp. (IART - Free Report) trades at a steep valuation discount, while recent margin gains and better operating execution offer support for the earnings outlook. The gap versus industry and market benchmarks gives value investors a reason to look closer.
The trade-off is that revenue growth remains modest, leverage is elevated and regulatory remediation is unfinished. That combination makes execution more important than the headline multiple alone.
IART’s Valuation Offers a Clear Discount
IART trades at 6.96X forward 12-month earnings, compared with 26.19X for its Zacks sub-industry, 21.43X for the broader Zacks Medical sector and 20.50X for the S&P 500. The discount is substantial across each benchmark.
Image Source: Zacks Investment Research
The stock also sits below its five-year median forward multiple of 11.00X. That suggests investors are still assigning a sizable discount for company-specific uncertainty despite the recent improvement in operating performance.
Integra’s Earnings Outlook Shows Measured Growth
The Zacks Consensus Estimate calls for 2026 revenues of $1.68 billion and earnings of $2.46 per share. For 2027, the consensus estimate stands at $1.74 billion in revenues and $2.56 per share in earnings.
Image Source: Zacks Investment Research
Projected earnings growth for the current fiscal year is 10.3%, while projected sales growth is 2.6%. The gap implies that margin delivery and cost execution will carry more weight than top-line expansion in supporting the earnings case.
IART’s Operating Improvements Strengthen the Case
Second-quarter 2026 adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by 16.7%. Adjusted EBITDA increased 10.1% to $78.4 million, while the adjusted EBITDA margin expanded 160 basis points to 18.7%.
Manufacturing efficiencies, lower remediation spending and margin-improvement initiatives supported the quarter. Integra also expects $25-$30 million of savings in 2026, with another $10-$15 million of annualized savings in 2027.
Competition remains relevant as supply reliability improves. Medtronic plc (MDT - Free Report) offers a broad neurosurgery portfolio spanning cranial repair, shunts, powered surgical equipment and navigation, while Stryker Corporation (SYK - Free Report) markets neurosurgical technologies including ultrasonic aspirators, high-speed drills and navigation systems. That breadth reinforces the importance of consistent execution for Integra.
Integra’s Debt and FDA Risks Argue for Patience
Net debt stood at $1.60 billion at the end of the second quarter, while total leverage was 4.1X, above management’s 2.5X-3.5X target range. Interest expense rose to $23.0 million from $21.0 million a year earlier, and management expects higher interest expense in the second half as it evaluates refinancing options.
Regulatory risk remains another constraint. The December 2024 FDA warning letter is unresolved, and related Class III premarket approvals cannot be cleared until relevant violations are corrected. Braintree is producing SurgiMend, but its premarket approval still requires a successful pre-approval inspection.
IART’s Value Score Stands Out Amid Mixed Signals
The valuation case is clear, but the operating and balance-sheet risks keep the setup from becoming a simple low-multiple story. Earnings improvement and cost savings help, while modest sales growth, refinancing costs and FDA remediation limit visibility.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B supports the discount argument, but the Growth Score of C, VGM Score of C and Momentum Score of D are less supportive. Because the Style Scores are designed to complement the Zacks Rank, the current mix favors a measured view rather than treating valuation alone as an unequivocal buy signal.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.